# Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

> **NCT00679588** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 4413 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Semuloparin Sodium
- **DRUG:** Enoxaparin sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00679588
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 4413 (ACTUAL)
- **Last updated:** 2013-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679588, "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00679588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*